Wednesday, April 06, 2022 7:01:38 PM
That we agree on. I never said they were, I only quoted what they said in their PR, as someone asked me a question.
I don't remember ever thinking it was a good use of their money, and still don't. The share structure, no dilution, and no share issuances are just fine without it.
Of course I always leave room for them surprising us, and for the possibility that I'm dead wrong.
Hl shmn tiny pharma at .0016.
I don't remember ever thinking it was a good use of their money, and still don't. The share structure, no dilution, and no share issuances are just fine without it.
Of course I always leave room for them surprising us, and for the possibility that I'm dead wrong.
Hl shmn tiny pharma at .0016.
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
